Source comparison
Comparisons: CJC-1295 vs. Other GH Secretagogues
CJC-1295 differs from GHRP-6, ipamorelin (GHS analogs), or sermorelin (shorter GHRH) primarily by its ultra-long half-life achieved through the Drug Affinity Complex (DAC) modification — a structural feature that researchers can examine further through the CJC
This comparison does not assign a generated winner or score.
- CJC-1295 differs from GHRP-6, ipamorelin (GHS analogs), or sermorelin (shorter GHRH) primarily by its ultra-long half-life achieved through the Drug Affinity Complex (DAC) modification — a structural feature that researchers can examine further through the CJC-1295 with DAC research peptide, which was investigated for its potential to enable sustained GH pulses as opposed to the more pulsatile action of short-acting agents.[pubmed.ncbi.nlm.nih.gov].
- CJC-1295
- GHRH analog + DAC
- 6–8 days [pubmed.ncbi.nlm.nih.gov], [academic.oup.com]
- Unapproved
- Pros: Investigated for weekly dosing; Cons: Hypersensitivity risk reported
- Sermorelin
- GHRH (1–29)
- <10 min
- Unapproved (compounded)
- Shorter action; generally considered to have a lower risk profile [mayoclinic.org]
- Ipamorelin
- GHS
- 2 hours
- May be used in synergistic combinations in investigational settings; generally considered to have milder side effects [mayoclinic.org]
- Tesamorelin
- GHRH analog
- ~30 min
- Approved (HIV lipodystrophy)
- Has proven safety and efficacy for its FDA-approved indication; daily dosing required [fda.gov]
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 24 hours
- Investigational
- Oral convenience; potential for appetite stimulation [mayoclinic.org]
- Certain combinations are referenced in preclinical literature, the CJC-1295 + Ipamorelin research blend represents one such pairing studied in laboratory settings for synergistic somatotropic axis signaling, though no published human RCTs validate this combination specifically.